Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.40
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0799
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2641
    +0.0019 (+0.15%)
     
  • USD/JPY

    151.2240
    -0.1480 (-0.10%)
     
  • Bitcoin USD

    70,483.25
    -410.05 (-0.58%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Weekly CEO Buys Highlight

- By Joy Hu

According to GuruFocus Insider Data, these are the largest CEO buys during the past week.

Odonate Therapeutics CEO bought 40,000 shares

Odonate Therapeutics Inc. (ODT) CEO and 10% Owner Kevin C. Tang bought 40,000 shares on Sept. 26 at a price of $19.75. The price of the stock has decreased by 1.72% since.


Odonate Therapeutics is a pharmaceutical company which is engaged in the development of therapeutics which improves and extend the lives of patients with cancer. It is developing tesetaxel, a chemotherapy agent used in the treatment of cancer. The company has a market cap of $521.97 million. Its shares traded at $19.41 as of Sept. 28.

Net loss for the second quarter was $19.39 million compared to $3.90 million for the prior-year period.

Tang also bought 90,000 shares on Sept. 20 at a price of $19.55. The price of the stock has decreased by 0.72% since.

Elanco Animal Health CEO bought 22,000 shares

Elanco Animal Health Inc. (ELAN) President, CEO and Director Jeffrey N. Simmons bought 22,000 shares on Sept. 24 at a price of $24.00. The price of the stock has increased by 45.38% since.

Elanco provides products and services to improve animal health and food-animal production in countries around the world. The company has a market cap of $12.43 billion. Its shares traded at $34.89 as of Sept. 28.

On Sept. 24 Elanco Animal Health announced the closing of its previously announced initial public offering of 62.9 million shares of its common stock at a price to the public of $24.00 per share.

See Remarks Sarena S. Lin bought 20,000 shares on Sept. 24 at a price of $24. The price of the stock has increased by 45.38% since.

Chief Accounting Officer James M. Meer bought 225 shares on Sept. 24 at a price of $24. The price of the stock has increased by 45.38% since.

See Remarks David S. Kinard bought 2,500 shares on Sept. 24 at a price of $24. The price of the stock has increased by 45.38% since.

See Remarks David Alan Urbanek bought 500 shares on Sept. 24 at a price of $24. The price of the stock has increased by 45.38% since.

Director R. David Hoover bought 10,000 shares on Sept. 24 at a price of $24. The price of the stock has increased by 45.38% since.

Y-mAbs Therapeutics CEO bought 31,250 shares

Y-mAbs Therapeutics Inc. (YMAB) CEO Moller San Pedro Claus Juan bought 31,250 shares on Sept. 25 at a price of $16.00. The price of the stock has increased by 66% since.

Y-mAbs Therapeutics is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center. The company has a market cap of $908.19 million. Its shares traded at $26.56 as of Sept. 28.

On Sept. 25, the company announced the closing of its initial public offering of 6.9 million shares of its common stock, including the exercise in full of the underwriters' option to purchase 900,000 additional shares of common stock, at a public offering price of $16.00 per share.

Director Ashu Tyagi bought 430,174 shares on Sept. 25 at a price of $16. The price of the stock has increased by 66% since.

Director James Healy bought 500,000 shares on Sept. 21 at a price of $16. The price of the stock has increased by 66% since.

Tallgrass Energy CEO bought 15,000 shares

Tallgrass Energy LP (TGE) President, CEO and 10% Owner David G. Dehaemers Jr. bought 15,000 shares on Sept. 24 at a price of $22.21. The price of the stock has increased by 6.17% since.

Tallgrass Energy is an energy company that transports crude oil and natural gas from the Rocky Mountains, Upper Midwest and Appalachian regions to the Rockies, the Midwest, eastern Ohio and other points. The company has a market cap of $6.61 billion. Its shares traded at $23.58 as of Sept. 28.

Net income for the second quarter of 2018 was $109.70 million.

Neogen CEO bought 4,300 shares

Neogen Corp. (NEOG) President and CEO John Edward Adent bought 4,300 shares on Sept. 26 at a price of $73.58. The price of the stock has decreased by 2.79% since.

Neogen, through its subsidiaries, develops, manufactures and markets a line of products dedicated to food and animal safety. The company has a market cap of $3.71 billion. Its shares traded at $71.53 with a price-earnings ratio of 56.37 as of Sept. 28.

Net income for the first quarter of fiscal 2019 which ended Aug. 31 was $15.24 million compared to the previous year's first quarter net income of $11.91 million.

Director James P. Tobin bought 500 shares on Sept. 26 at a price of $73.37. The price of the stock has decreased by 2.51% since.

For the complete list of stocks that were bought by their company CEOs, go to: CEO Buys.

Disclosure: I do not own stock in any of the companies mentioned in the article.

This article first appeared on GuruFocus.


Advertisement